Clinical Trials Sponsored by Suzhou Neologics Bioscience Co., Ltd.

Total 842 results

Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

B-Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Diffuse, Large B-Cell, Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.
Fortrea

Completed

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) (ORIENT-15)

Esophageal Squamous Cell Carcinoma

France, Spain, Belgium, Australia, United States, China, Hungary
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Not yet recruiting

A Study of WJ05129 in Advanced Malignant Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors

China
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Fudan University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
Peking University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
RenJi Hospital
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.

Unresectable Locally Advanced Pancreatic Cancer

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Advanced Squamous Cell Lung Cancer

Advanced Lung Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Harbin Medical University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Hepatic Carcinoma

China
Synermore Biologics (Suzhou) Co., Ltd.
Simoon Record Pharma Information Consulting Co., Ltd.

Completed

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

RNA Virus Infections | Virus Diseases | Mononegavirales Infections | Rabies | Rhabdoviridae Infections | Communicable Disease

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC

Pancreatic Adenocarcinoma Metastatic

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
M.D. Anderson Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Cancer of Unknown Primary

Cancer of Unknown Primary Site

United States
Chunrui Li
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#

Relapsed/Refractory Multiple Myeloma

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors

Pediatric Cancer

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (CONTINUUM)

Nasopharyngeal Neoplasms

China
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Suzhou Alphamab Co., Ltd.

Recruiting

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Knee Arthroplasty, Total

China
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Peking University Cancer Hospital & Institute
Innovent Biologics (Suzhou) Co. Ltd.

Completed

HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma

Liver Metastases | Esophageal Squamous Cell Carcinoma | Hepatic Arterial Infusion Chemotherapy

China
Norroy Bioscience Co., LTD

Recruiting

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients

Prostate Cancer

China
Norroy Bioscience Co., LTD

Recruiting

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Metastatic Castration-resistant Prostate Cancer

China
SK Bioscience Co., Ltd.

Completed

Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety Study of NBP615 in Healthy Female

Cervical Cancer

Korea, Republic of
Norroy Bioscience Co., LTD

Recruiting

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients

Clear Cell Renal Cell Carcinoma Metastatic

China
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

Influenza

Korea, Republic of
Suzhou Kerui Medical Technology Co., Ltd
Suzhou Mingshi Optical Technology Co., Ltd

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of Defocusing Lenses in Delaying Myopia Progression

Myopia

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Advanced Non-small Cell Lung Cancer
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Not yet recruiting

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Systemic Sclerosis | Immune Thrombocytopenia | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Primary Biliary Cholangitis
MediLink Therapeutics (Suzhou) Co., Ltd.

Not yet recruiting

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Advanced Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases

Patients With Bone Metastases

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Cervical Carcinoma

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

KRAS G12C Mutant Advanced Solid Tumors

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Solid Tumor | KRAS Mutation-Related Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Advanced Colorectal Cancer

China
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Solid Tumor

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG0895.HCl in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China

Clinical Trials Sponsored by Suzhou Neologics Bioscience Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations